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The Editorial on the Research Topic
Systems Biological Aspects of Pituitary Tumors
Pituitary adenomas are a category of neoplasms with a high degree of heterogeneity that occur in 
the central regulatory organ pituitary, which plays important roles in the hypothalamus–pituitary-
targeted organ axis systems that impact on important physiological functions of human body (1–3). 
Rapidly developed omics and systems biology (4–6) impact on treatment of pituitary adenomas and 
gradually change the paradigms from the traditional single-factor strategy to a multi-parameter 
systematic strategy. A pituitary adenoma is a complex, chronic, and whole-body disease that alters 
the genome, transcriptome, proteome, and metabolome and involves multiple factors, processes, 
and consequences (7–9). Pituitary adenomas gradually change in the model of predictive screen-
ing, diagnosis, and prognostic assessment of pituitary adenomas that previously only depended on 
changes of serum single-hormone change and pituitary imaging, and in the therapeutic model of 
cancer from general radiotherapy and chemotherapy to a personalized strategy (8, 9).
This present issue focuses on systems biological aspects of pituitary adenomas, which contains 
four topics. (i) The first topic addressed vitamin D status and calcium–phosphate homeostasis 
in acromegaly patients (Halupczok-Żyła et al.). Vitamin D deficiency and alteration in calcium–
phosphate balance are associated with a wide spectrum of diseases, such as cancer, diabetes, 
cardiovascular disease, and respiratory disease. Data demonstrate that acromegaly patients are 
at the higher risk of vitamin D deficiency and have a tendency to a lower level of calcium and 
higher level of inorganic phosphate. Data suggest the importance of inorganic calcium–phosphate 
homeostasis in the pathogenesis of acromegaly patients (growth hormone pituitary adenomas) 
from the systemic view point. (ii) The second topic addressed the alteration in the chemokine 
network in pituitary adenomas from a systemic view (Grizzi et al.). Chemokines are a category 
of inflammatory mediators that exert their roles through typical and atypical chemokine receptor 
signaling pathways. An alteration of chemokines and receptors is associated with cancer and 
inflammatory diseases. The chemokine network is proposed as the target of biomarker and new 
therapeutic approach for pituitary adenomas. (iii) The third topic addressed the proteomic vari-
ations in pituitary adenomas (Zhan and Wang). Proteomics is the key component of functional 
genomics and systems biology. Much progress has been achieved in pituitary adenoma proteomics 
to expand and enrich the systems biology analysis of pituitary adenomas. This topic emphasized the 
significance of variations in proteome and protein molecular networks for personalized and precise 
studies of pituitary adenomas. (iv) The fourth topic focused on molecular network variations in 
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different subtypes of non-functional pituitary adenomas (Zhan 
and Long). That topic emphasized the integrative molecular 
networks derived from multiple omics data at the genome, 
transcriptome, proteome, peptidome, and metabolome levels, 
and on their variations in different subtypes of non-functional 
pituitary adenomas. These studies will benefit discovery of 
effective and reliable biomarkers and therapeutic targets for 
personalized and precise studies of highly heterogeneous non-
functional pituitary adenomas.
It is clear that the systems biological aspects of pituitary adeno-
mas cover a very wide range from systemic concepts to analytic 
methods; from genome, transcriptome, proteome, and metabo-
lome to interactome; from single omics to integrative omics; 
from panel analysis to molecular network analysis; from genetic 
feature to phenotype; and from common features to individual 
characteristics, to investigate the diversity of pituitary adenomas 
that include functional and non-functional pituitary adenomas 
and their subtypes (10–15). It must be clearly mentioned that 
this issue contains only a limited fraction of the very important 
systems biological aspects of pituitary adenomas.
This research topic serves as a modest spur to induce research-
ers who study systems biology strategies to come forward with 
its valuable contributions to research and clinical practice of 
pituitary adenomas.
From the point of view of systematic strategies in pituitary 
adenomas, it is necessary for future studies to systematically 
investigate variations in the genome, transcriptome, proteome, 
peptidome, and metabolome in pituitary adenoma tissue and 
body-fluids (cerebrospinal fluid, CSF; serum/plasma), and espe-
cially for different subtypes of pituitary adenomas (7, 9). Systems 
biology approaches will be used to integrate all experimental data 
and all clinical information of an individual and to propose cor-
responding molecular networks specific to a pituitary adenoma 
in order to achieve efficient prediction screening, early stage 
diagnosis, prognostic assessment, and individualized and precise 
prevention and therapy (16, 17).
Future issues will collect different levels of omics studies, 
especially the integrative omics studies together with genetics 
and clinical information with developed advanced computational 
biology approaches.
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